Cellular metabolic pathways contribute to many aspects of viral infection and may have pro-viral as well as antiviral functions. However, specific mechanisms for metabolic regulation of antiviral immunity are not well understood. Peroxisomes are essential sites of fatty acid metabolism and regulate immune signaling. We investigated the function of peroxisomal metabolism in herpesvirus infection and innate immunity in vivo and ex vivo. We found that induction of peroxisomal activity through the activation of the nuclear receptor PPAR-a enhanced herpesvirus replication. PPAR-a activation increased reactive oxygen species (ROS), which inhibited activation of stimulator of interferon (STING), a signaling molecule in the cytosolic DNA sensing pathway that induces antiviral type I interferon. Importantly, stimulation of peroxisomal activity in mice enhanced herpesvirus replication and pathogenesis comparable to levels observed previously in type I interferon receptor knockout mice. These findings are the first to indicate that peroxisomal lipid metabolism and ROS directly regulate immunity to cytoplasmic DNA.
Introduction
The metabolic machinery of the cell is a key component of host defense and immune cell function. Eukaryotic host cells adapt their cellular environments to enhance host defense against invading viruses. Conversely, viruses evolve ways to manipulate host cell metabolism to promote virus replication.
Intermediates of cellular metabolism are important signaling molecules that alter immune defense pathways (O'Neill et al., 2016) . For example, citrate and succinate from the tricarboxylic acid (TCA) cycle modify macrophage function by enhancing nitric oxide and cytokine production, respectively. The interrelatedness of immune cell function and metabolic pathways, including the TCA cycle, oxidative phosphorylation, and fatty acid oxidation have been comprehensively studied in mitochondria. However, peroxisomes, which are sites of lipid metabolism, also have the potential to modify immune cell function. Peroxisomes synthesize phospholipids and bile acids and oxidize very long, branched chain, and polyunsaturated fatty acids. As their name implies, peroxisomes produce significant amounts of hydrogen peroxide and other reactive oxygen species (ROS). ROS have been widely implicated in inflammatory processes, particularly for NFkB signaling and inflammasome activation (Forrester et al., 2018) .
Peroxisomes are important sites of antiviral immunity. RIG-I-like receptors (RLRs) in the cytoplasm detect viral RNA and activate the adapter protein mitochondrial antiviral signaling protein (MAVS). MAVS is anchored on not only the outer mitochondrial membrane, but also on peroxisomes. Peroxisomal MAVS generates an early antiviral response that is unique from mitochondrial MAVS and independent of interferon-b (IFNb) (Dixit et al., 2010) . Certain RNA viruses, including flaviviruses, induce loss of peroxisomes and impaired antiviral immune responses (You et al., 2015) . These data suggest that peroxisomes function in antiviral immunity to RNA viruses. However, it is unclear whether peroxisomes function in innate immunity to DNA viruses and cytoplasmic DNA.
Herpesviruses are enveloped DNA viruses that establish chronic infections in their hosts.
After acute replication, herpesviruses enter a quiescent phase, termed latency, for the life of the host. Latency is characterized by limited viral gene expression and no viral progeny production. However, latency is punctuated with brief periods of viral reactivation leading to viral progeny production and spread of the virus to new cells and hosts. In order to enter and maintain viral latency, herpesviruses must manipulate the cellular environment to favor viral persistence and evade immune recognition (Barton et al., 2011) .
Peroxisomal proliferation is a notable feature of herpesvirus infection. The g-herpesvirus Kaposi's sarcoma associated herpesvirus (KSHV), the a-herpesvirus Herpes simplex virus (HSV)-1, and the b-herpesvirus human cytomegalovirus (HCMV) all increase peroxisomes in infected cells (Beltran et al., 2018; Sychev et al., 2017) . Moreover, each of these viruses encodes viral proteins (vFLIP for KSHV, vMIA for HCMV, and VP16 for HSV-1) that target peroxisomes, suggesting that modulation of peroxisomal function is important for the virus (Choi et al., 2018; Magalhães et al., 2016; Zheng and Su, 2017) . A recent report found that HCMV and HSV-1 induced peroxisome biogenesis and plasmalogen production, leading to enhanced virus envelopment and lytic replication (Beltran et al., 2018) . However, these data do not address the potential role of peroxisome biogenesis in chronic infection with a herpesvirus.
KSHV latent cell survival requires peroxisomal lipid metabolism, suggesting that KSHV modulates peroxisomal lipid metabolism to support latent infection (Sychev et al., 2017) .
In order to examine the role of peroxisome metabolism in herpesvirus infection in vivo
we employed a murine model of g-herpesvirus infection, murine gammaherpesvirus-68 (MHV68), to study the effect of peroxisomal activation on lytic and latent g-herpesvirus infection.
Similar to the human g-herpesviruses, KSHV and Epstein Barr virus (EBV), this virus establishes latent infection in the host and reactivates in response to various immune and chemical signals (Barton et al., 2011; Reese, 2016; . MHV68 also leads to lymphomas and tumors in immunocompromised hosts, similar to the human viruses (Barton et al., 2011) .
Here we investigated the consequences of increased peroxisomal metabolism on herpesvirus infection and induction of antiviral immune responses. We induced peroxisomal metabolism with fibrates, which are drugs used in humans to lower serum triglycerides levels (Staels et al., 1998) . These drugs are agonists for peroxisome proliferator activated receptor (PPAR)-a, which is a member of a subfamily of nuclear hormone receptors that drive expression of genes involved in fatty acid oxidation (Issemann and Green, 1990; Reddy and Hashimoto, 2001) . We discovered that activation of PPAR-a increased virus replication and inhibited type I interferon production following DNA-virus infection or direct stimulation of the cyclic GMP-AMP synthase (cGAS)/stimulator of interferon (STING) pathway. Importantly, treatment of mice with PPAR-a agonist led to increased herpesvirus replication, heightened lethality, and enhanced herpesvirus reactivation from latency in agonist-treated mice. Our data suggest that activation of PPAR-a suppresses cytoplasmic DNA sensing by generating high ROS that inhibit STING activation, leading to reduced type I interferon and impaired immunity to viral infections.
Results

Activation of PPAR-a promotes MHV68 replication.
To examine the effects of increased peroxisome biogenesis and fatty acid oxidation on herpesvirus infection, we treated macrophages with fibrates to stimulate peroxisome metabolism. Bone marrow derived macrophages were treated with PPAR-a agonists, fenofibrate or WY14643, and infected them with MHV68. Using a flow cytometric assay to determine the amount of lytic viral protein expressed on infected cells , we compared PPAR-a agonist treatment with agonists for two closely related nuclear receptors, PPAR-b/d and PPAR-g (GW501516 and rosiglitazone, respectively). We found that PPAR-a agonists fenofibrate and WY14643 both increased expression of lytic viral proteins on infected macrophages compared with untreated cells or cells treated with GW501516 or rosiglitazone ( Figure 1A ). MHV68 replication at either low or high multiplicity of infection (MOI) was also increased in macrophages treated with fenofibrate or WY14643 compared with untreated cells ( Figure 1B , C, Supplemental Figure 1 ). Treatment with agonist had no effect on virus replication in macrophages isolated from Ppara -/mice, suggesting that PPAR-a is critical for agonist effects ( Figure 1D ). We tested whether stimulation of PPAR-a affected replication of a bherpesvirus that also infects macrophages and found that replication of murine cytomegalovirus (MCMV) was also increased by PPAR-a agonist (Supplemental Figure 2) . Thus, PPAR-a stimulation increases herpesvirus replication in a PPAR-a-dependent manner.
PPAR-a stimulation suppresses type I IFN production in a STING-dependent manner
To broadly assess the impact of PPAR-a agonist on cells infected with virus, we performed RNA sequencing analysis on macrophages infected with virus and treated with WY14643. Six hours after infection, uninfected/vehicle treated, MHV68+/vehicle treated, uninfected/WY14643 treated cells, and MHV68+/WY14643 treated macrophages were prepared for RNA-seq. Pathway analysis of differentially expressed genes revealed that virus infection in both vehicle-treated and WY14643-treated cells increased expression of interferon responsive genes, genes involved in inflammation, and NFkB pathway genes (Figure 2A , Supplemental   Table 1 ). However, PPAR-a stimulation reduced the magnitude of upregulation in infected cells.
Thus, PPAR-a stimulation attenuates the early antiviral response in infected cells.
To confirm the sequencing results, we quantified expression of a subset of interferon stimulated genes. We measured Isg20, Isg15, and Cxcl10 and confirmed that expression of these genes is reduced in both uninfected and infected macrophages treated with WY14643 ( Figure 2B ). We also measured expression of Ifnb and found that expression is reduced after agonist treatment ( Figure 2B ). These data suggest that PPAR-a stimulation suppresses the interferon response at baseline and after viral infection.
Because of the suppression of the early antiviral response, we tested whether the effects of PPAR-a stimulation depended on the type I interferon response. To test this, we examined viral growth in wildtype and Ifnar -/macrophages with and without agonist treatment. As expected, virus grew substantially more in Ifnar -/cells compared with wildtype cells. PPAR-a stimulation did not further increase virus replication in the knockout cells (Supplemental Figure   3 ). Thus, PPAR-a stimulation effects depend on type I interferon.
MHV68 is a DNA virus that induces interferon downstream of the cGAS/STING pathway; therefore, we hypothesized that PPAR-a stimulation could antagonize the early induction of interferon after recognition of cytoplasmic DNA. Cytoplasmic DNA is sensed by cGAS, leading to activation of endoplasmic reticulum adapter molecule STING. STING phosphorylates TBK1 and IRF3, leading to transcription of IFNb. IFNb then signals through the type I IFN receptor to induce interferon stimulated gene expression and more IFNb expression. To test if PPAR-a stimulation could suppress IFNb induction after direct activation of STING, macrophages were treated with vehicle or agonist and stimulated with DMXAA, a murine agonist of STING. We found that PPAR-a stimulation suppressed IFNb expression after DMXAA transfection ( Figure   2C ). As expected, the PPAR-g and PPAR-d agonists rosiglitazone and GW-501516 did not suppress IFNb expression after DMXAA treatment (Supplemental Figure 4 ). Moreover, PPAR-a stimulation suppressed production of IFNb protein ( Figure 2D ). These data suggest that PPARa stimulation antagonizes the induction of interferon production downstream of the STING DNA sensing pathway.
To test if suppression of IFNb depended on STING, we treated Sting -/macrophages with PPAR-a agonist and infected with MHV68. We found that PPAR-a stimulation no longer increased virus replication in cells deficient in STING ( Figure 2E ). We examined activation of TBK1 and IRF3 and found that PPAR-a stimulation suppressed DMXAA-induced phosphorylation of both proteins ( Figure 2F ). These data indicate that the effects of PPAR-a agonist depend on STING expression and suggest that PPAR-a stimulation antagonizes the initial induction of IFNb after recognition of cytoplasmic DNA.
PPAR-a stimulation induces oxidative stress
We wondered if PPAR-a agonist effects could promote virus replication even if cells were treated with agonist after infection, or if the effects of agonist required pretreatment. To test this, we compared three different treatment protocols. We pretreated, as above, with PPAR-a agonist overnight and replaced agonist in the media following infection with MHV68.
We compared this with pretreatment only (pre) or post treatment only (post). We found that pretreatment with PPAR-a agonist was required to increase MHV68 replication ( Figure 3A ). We found no increase in virus replication when cells were treated post-infection with agonist. We also found that pretreatment alone was sufficient to increase virus replication. These data suggest that PPAR-a stimulation is altering the cellular environment prior to infection in such a way that enhances virus replication.
In order to determine how PPAR-a stimulation was altering the cellular environment to promote virus replication and impair interferon induction, we examined vehicle and WY14643only treatments from our sequencing data. PPAR-a agonist treated cells displayed increased antioxidant response pathways, indicating a possible increase in oxidative stress in PPAR-a agonist treated cells ( Figure 3B , Supplemental Table 2 ). To confirm these results, we analyzed expression of antioxidant genes in untreated or PPAR-a agonist treated macrophages and confirmed increased expression of Mgst1, Gsr, Slc7a11, Gstm1, Gclm, and Cd36 in agonist treated cells ( Figure 3C ). PPAR-a agonist treatment of macrophages also promoted increase total ROS ( Figure 3D ). These results are comparable to previous data indicating that PPAR-a agonist treatment increases b-oxidation of fatty acids in peroxisomes and enhances production of ROS (Reddy and Hashimoto, 2001; Teissier et al., 2004) .
Given that PPAR-a stimulation increased antioxidant gene expression and ROS production and that these effects correlated with increased viral replication, we next tested whether increased ROS suppressed IFNb production. Macrophages were treated with hydrogen peroxide (H2O2) and stimulated with DMXAA. H2O2 treatment suppressed DMXAAinduced IFNb production ( Figure 3E ). In addition, N-Acetyl-L-cysteine (NAC), an antioxidant, partially neutralized the effects of H2O2 ( Figure 3E ). H2O2 treatment suppressed phosphorylation of TBK1 and IRF3 ( Figure 3F ). This indicates that increased oxidative stress suppresses the cGAS/STING pathway after activation with cytoplasmic DNA.
To determine if cells that have constitutive high levels of ROS have impaired interferon responses, we examined that antiviral response in nuclear factor E2-related factor 2 (NRF2) deficient cells. NRF2 is a transcription factor that regulates antioxidant responses by binding to antioxidant response elements (ARE) found in promoters of detoxication enzymes. NRF2 activity is regulated by KEAP1, and KEAP1 under non-stressed conditions promotes NRF2 ubiquitylation. When cells are under oxidative stress, NRF2 is released from KEAP1 and drives antioxidant gene expression (Nguyen et al., 2009 ). Nrf2 -/cells do not induce antioxidant genes and have high levels of ROS (Chan et al., 1996; Itoh et al., 1997; McMahon et al., 2001) . We confirmed that Nrf2 -/macrophages had increased ROS ( Figure 3G ). When we stimulated Nrf2 -/macrophages with DMXAA they induced less Ifnb expression compared to wildtype cells ( Figure   3H ). Additionally, PPAR-a agonists did not further suppress Ifnb transcript production from knockout cells ( Figure 3H ). Together, these data suggest that ROS can suppress IFNb downstream of direct STING activation.
To determine if the lower levels of IFNb expressed in Nrf2 -/macrophages led to increased viral replication, we infected Nrf2 -/and wildtype macrophages with MHV68. We observed increase viral protein expression after infection in Nrf2 -/macrophages, indicating that virus replicated better in cells with higher levels of ROS and decreased IFNb ( Figure 3I ).
PPAR-a stimulation increases virus replication and lethality in mice.
Because we found that PPAR-a stimulation in vitro suppressed interferon production, we hypothesized that agonist treatment of mice infected with MHV68 would alter herpesvirus replication. Previously published work established that mice deficient in the IFNa/b receptor (IFNAR) have increased viral replication and enhanced susceptibility to MHV68 (Dutia et al.) .
To determine if PPAR-a stimulation increased MHV68 replication in vivo, we injected wildtype and Ppara -/mice with WY14643 or vehicle control for 7 days, starting 3 days prior to infection and continuing for 4 days after infection ( Figure 4A ). Mice were infected with a dose of MHV68 that does not cause lethality in wildtype mice treated with the drug vehicle. However, wildtype mice injected with PPAR-a agonist succumbed to infection ( Figure 4B) , at a frequency similar to type I interferon receptor deficient mice (Dutia et al.) . Moreover, Ppara -/mice treated with agonist or vehicle all survived infection with MHV68, indicating that the lethality observed in wildtype mice treated with agonist is PPAR-a dependent ( Figure 4C ). Using a luciferase-tagged MHV68 (MHV68-M3FL) we imaged mice infected with virus over multiple days during acute infection (Hwang et al., 2008; . We found that mice treated with WY14643 had increased virus replication compared to vehicle treated mice, and that this increase in virus replication was PPAR-a dependent ( Figure 4D , E). These data suggest that PPAR-a stimulation significantly increased MHV68 acute replication.
To determine if the interferon response was altered by PPAR-a stimulation, we analyzed interferon stimulated gene expression in the peritoneal cells for vehicle-treated and agonisttreated mice. We found that expression of Isg20 and Cxcl10 was decreased in agonist treated mice ( Figure 4F ), indicated that treatment with PPAR-a agonist during acute infection suppressed the interferon response.
PPAR-a stimulation induces herpesvirus reactivation.
We hypothesized that if PPAR-a stimulation induces ROS and impairs the production of interferon, then PPAR-a agonist may enhance MHV68 reactivation from latency. Previous work demonstrated increased reactivation from latency in mice deficient in IFNAR or in mice that received a blocking antibody for IFNAR (Barton et al., 2005; Steed et al., 2006) . Additionally, oxidative stress induces KSHV reactivation from latency in cell lines (Li et al., 2011; Ye et al., 2011) . We examined PPAR-a expression in latently infected spleens and peritoneal exudate cells (PECs) and found that latent virus infection induced PPAR-a expression ( Figure 5A ). To determine if PPAR-a stimulation could increase virus reactivation, we infected mice with MHV68-M3FL and waited for one month to establish latency prior to treatment with WY14643 ( Figure 5B ). By this time there is little to no luciferase expression from the virus, indicating that the virus is quiescent (Hwang et al., 2008; . Upon virus reactivation, luciferase is expressed and quantitated with an in vivo bioluminescence reader. When mice were treated with vehicle control or WY14643 alone there was no measurable virus reactivation ( Figure 5C ). However, we found previously that reactivation of MHV68 requires 2 signals . Neither administration of IL-4, a direct inducer of herpesvirus latent-to-lytic gene expression, nor administration of a blocking antibody to IFNg, a suppressor of virus reactivation, was sufficient to induce MHV68 reactivation. However, the combination of IL-4 and anti-IFNg treatment induced significant virus reactivation. Therefore, we hypothesized that if PPAR-a agonist was suppressing type I IFN, then a positive inducer of herpesvirus gene expression may be required to promote MHV68 reactivation. To test this, we combined WY14643 with long-lasting IL-4 complexes (IL-4c). When compared to IL-4c alone, WY14643 alone, or vehicle the combination of WY14643 and IL-4c induced significant virus reactivation from latency ( Figure 5C, D) . Thus, PPAR-a stimulation induces herpesvirus reactivation from latency.
Discussion
We determined that induction of peroxisome metabolism and b-oxidation of fatty acids by PPAR-a agonist increases virus replication and reactivation. In macrophages, PPAR-a stimulation increased virus replication and suppressed the induction of an interferon response in a STING-dependent manner. PPAR-a stimulation induced oxidative stress in cells and high levels of oxidative stress impaired STING-induced interferon production. This is the first evidence that PPAR-a activation and peroxisomal metabolism regulate the cytoplasmic DNAsensing pathway and IFNb production downstream of STING. PPAR-a stimulation significantly increased herpesvirus replication in mice, leading to increased lethality of agonist-treated mice.
Not only did PPAR-a stimulation increase herpesvirus acute replication, but PPAR-a agonist also increased MHV68 reactivation from latency in combination with IL-4 treatment. These data are the first to indicate that, during latency, peroxisomes modulate interferon production.
Peroxisomal metabolism may represent a strategy used by herpesviruses to fine-tune interferon production for the purposes of modulating virus latency and reactivation.
Metabolism is recognized as an important regulator of immunity. Metabolic reprogramming of macrophages, in particular, is essential for modifying their inflammatory phenotype and function. Glycolysis drives inflammatory macrophage responses, whereas high fatty acid oxidation was long thought to support anti-inflammatory macrophage responses (den because oxidation of palmitate promotes the production of mitochondrial ROS, which induces inflammasome activation (Hall et al., 2013; Moon et al., 2016) . Moreover, mitochondrial ROS promotes the production of the proinflammatory cytokines IL-1b, IL-6, and TNFa following LPS stimulation of macrophages (Bulua et al., 2011) . Our data adds another level of complexity to the role of ROS in inflammation. Peroxisomes are essential for the metabolism of very long chain fatty acids and they produce significant quantities of ROS. Our data indicates that ROS, perhaps derived from peroxisomal b-oxidation of very long chain fatty acids, impairs STING activation and interferon production. Further work is needed to determine the source of ROS.
However, our data thus far suggests that the induction of peroxisomal metabolism and fatty acid oxidation, leading to high ROS production, alters innate immune signaling.
These data reveal that peroxisomal metabolism and increased ROS production regulates the cytoplasmic DNA sensing pathway. Previously, the adapter molecule MAVS that signals downstream of RNA recognition was found localized to not only mitochondria, but also peroxisomes. Interestingly, the peroxisomal localization of MAVS dictates unique signaling pathways and gene responses distinct from mitochondrial MAVS (Dixit et al., 2010; Odendall et al., 2014) . Together these data along with our data indicate that peroxisomes are critical organelles for the induction of innate immune signals, either through localization of critical signaling molecules or production of metabolites that regulate immune signaling.
Herpesviruses use multiple mechanisms to maintain latency in the host and peroxisomal metabolism is a putative novel mechanism. To avoid clearance, herpesviruses evade immune recognition by downregulating antigen presentation, expressing viral proteins that regulate the interferon pathway, inhibiting cell cycle arrest and apoptosis, and encoding various molecular mimics. This is indicative of a long evolutionary relationship with the host. It also suggests that herpesviruses modify numerous pathways within the host cell to tune the balance between latency and reactivation. Peroxisomal proliferation is a feature of herpesvirus infection, but the function of peroxisomal biogenesis during latency has been elusive. We show that PPAR-a expression is increased during herpesvirus latency, and that peroxisomal metabolism suppresses interferon production, leading to viral reactivation from latency. This suggests that peroxisomes and the redox balance of the cell may regulate latency by adjusting the production of type I interferon.
A key remaining question is how ROS regulates STING activation. Recent structural data provide numerous insights into the mechanism of cGAMP activation of STING (Ergun et al., 2019; Shang et al., 2019) . STING dimers in the ER form polymers upon binding to cGAMP and disulfide bonds in the cytosolic domain stabilize STING polymers. These inter-dimer crosslinks are important for STING activation. One possibility is that increased oxidative stress leads to oxidation of cysteine residues in the cytosolic domain, which interferes with the polymerization and activation of STING.
Overall, our work suggests that metabolism and particularly ROS have both proinflammatory and anti-inflammatory functions. These results have implications for therapies that induce or suppress oxidative stress, either for the treatment of infection, cancer or autoimmune disease.
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The authors declare no competing interests. (H) Macrophages isolated from WT or Nrf2 -/mice were pretreated for 16 hours with fenofibrate, WY14643, or vehicle. Cells were transfected with DMXAA and expression of Ifnb transcript was quantitated 2 hours later. Relative expression of Ifnb was normalized to Gapdh. n=5 Data all shown as mean ± SD; * p<0.05, ** p<0.01, *** P<0.001, statistical analysis was conducted using one-way ANOVA or two-way ANOVA test.
(I) Macrophages isolated from WT or Nrf2 -/mice were infected with MHV68 at a MOI=5 for 24 hours. Cells expressing MHV68 lytic proteins were quantified by FACs assay. N=3 from independent experiments. Data all shown as mean ± SD; * p<0.05, ** p<0.01, statistical analysis was conducted using oneway ANOVA or unpaired t-test.
Figure 4. PPAR-a stimulation in mice increases virus replication and lethality.
(A) Schematic for acute replication of MHV68 in mice. Mice were treated with either vehicle control (15% HS15) or WY14643 (100 mg/kg) for 7 days, starting 3 days before infection. Mice were infected intraperitoneally with MHV68-M3FL at dose of 10 6 PFU. Acute replication of virus was measured at d2, d4 and d7 after infection using an IVIS bioluminescent imager. Survival of mice was monitored until 20 days after infection. Data all shown as mean ± SD; * p<0.05, ** p<0.01, *** P<0.001, statistical analysis was conducted using one-way ANOVA or two-way repeated measures ANOVA test. Data all shown as mean ± SD; *** P<0.001, statistical analysis was conducted using two-way repeated measures ANOVA test.
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EXPERIMENTAL MODELS AND SUBJECT DETAILS
Animals
METHOD DETAILS
MHV68 acute replication in mouse
Experiments were carried out using 8-12 weeks old male mice under the protocol approved by IACUC. Mice were injected intraperitoneally with either vehicle control (15% HS15 in normal saline) or WY14643 (100mg/kg) for 1 week starting from 3 days before virus infection. Mice were then infected with MHV68-M3FL at the dose of 10 6 PFU through intraperitoneal route (Hwang et al., 2008; . To quantify virus-encoded luciferase expression, mice were weighed and injected with 150 mg/kg of D-Luciferin (GOLDBIO) prior to imaging using IVIS Lumina III In Vivo Imaging System (PerkinElmer). Total flux (Photons/second) of the abdominal region was determined using Living Image software (PerkinElmer). Survival of the mice were recorded until 20 days after infection.
MHV68 reactivation in mouse
8-12 weeks old mice were injected intraperitoneally with MHV68-M3FL at the dose of 10 6 PFU (Hwang et al., 2008; . Four weeks after infection, mice were injected with either vehicle control (15% HS15 in normal saline), complex of 5 µg of IL-4 (PEPROTECH) and
25 µg of anti-IL-4 (BioXcell, clone 11B11) , WY14643 (100 mg/kg) or both IL-4 complex (IL-4c) and WY14643. The reactivation of MHV68 were then quantified by IVIS Lumina III after administration of D-Luciferin.
Cell culture
Bone marrow derived macrophages were differentiated in DMEM with 10% FBS supplemented with 1% glutamine, 1% HEPEs and 10% CMG14 supernatant for 7 days .
3T12 cells were maintained in DMEM with 5% FBS supplemented with 1% glutamine and 1%
HEPES.
Virus infection
Fully differentiated BMDMs were seeded on 24 well plates (1.5x10 5 cells per well) or 6 well plate (10 6 cells per well 
Flow cytometry for MHV68 lytic proteins positive cells
To determine the percentage of cells that expressing lytic proteins of MHV68 infection, cells were harvested 24 hours after infection, and fixed with 2% formaldehyde, blocked with 10% mouse serum and 1% Fc block (CD16/32, BioLegend), then stained with polyclonal rabbit antibody to MHV68 (1:1000) Weck et al., 1997) , followed by secondary goat anti-rabbit Alexa Fluor-647 (Invitrogen).
Transfection
Cells were seeded on 6 well plates and treated as needed. Cells were transfected with STING ligand (DMXAA, 10 µg/ml, InvivoGen) using Lipofectamine 3000 (Thermo Fisher Scientific)
according to the manufacturer's protocol.
Plaque assay
The concentration of virus was titered in 3T12 cells. The frozen samples containing viruses were thawed in incubator, the serial diluted samples were then added on the monolayer of 3T12 cells. After an hour of absorption, the cells were then covered with 1% methylcellulose. Plates were incubated at 37 °C for 7 days, and the plaques were stained with 0.1% crystal violet.
Western blot
Cells were lysed with RIPA buffer (150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 25 mM Tris with protease inhibitor cocktail). Protein concentration were determined using Bradford assay (Bio-Rad). Equal amounts of protein were resolved by SDS-PAGE, transferred to nitrocellulose membrane, immunoblotted with specific primary and secondary antibodies, and developed using Luminata Forte Western HRP substrate (Millipore).
QRT-PCR
BMDMs in 6 well plates were either infected with MHV68 at MOI=5 for 6 hours or transfected with STING ligand DMXAA at 10 µg/ml for 2 hours. RNA was extracted using Qiagen RNeasy Mini Kit (Qiagen) and reverse transcribed into cDNA using SuperScript VILO cDNA Synthesis Kit (Invitrogen). Relative quantification of target genes was determined using PowerUp SYBR Green Master Mix in a QuantStudio 7 Flex real time PCR system.
IFNb ELISA Assay
BMDMs were seeded in 24 well plates, the next day, cells were treated with either vehicle control or WY14643 for 16 hours. Cells were then transfected with DMXAA at the concentration of 10 µg/ml. Supernatant of cells were collected at 24 hours after transfection and frozen at -80 °C. The concentration of IFNb in the supernatant was determined with PBL IFN Beta ELISA Kit (PBL Assay Science).
Total ROS measurement
The total ROS production was determined using ROS-ID Total ROS detection kit (Enzo) according to the manufacture's protocol. Cells were seeded on 24 well plates, and treatment with indicated compounds or DMSO as vehicle control for 6 hours, followed by incubation with oxidative stress detection reagent for 30 mins at 37 °C. The fluorescence of the detection reagent upon oxidation was analyzed by flow cytometry using a FACSCalibur (BD Biosciences).
RNA seq and data analysis
RNA samples were extracted with RNeasy Mini Kit (Qiagen) and RNA library was prepared using TruSeq Stranded mRNA Sample Preparation Kit (Illumina). Samples were sequenced on NextSeq 500/500 sequencer (Illumina) with SE-85. RNA seq data is normalized and analyzed based on the use of "internal standards" (Rocke and Durbin, 2001 ) that characterize some aspects of the system's behavior, such as technical variability, as presented elsewhere (Dozmorov and Centola, 2003; Dozmorov and Lefkovits, 2009 ). The two-step normalization procedure and the Associative analysis functions are implemented in MATLAB (MathWorks, MA) and available from authors upon request. Functional analysis of identified genes was performed with Ingenuity Pathway Analysis (IPA; Ingenuity System). The sequencing data has been deposited in the European Nucleotide Archive under the accession number PRJEB33753.
QUANTIFICATION AND STATISTICAL ANALYSIS
All data are presented as mean ± SD. Statistical comparisons were performed using Graphpad Prism 7.0 software. Data were compared using unpaired two-tailed t test, one-way or two-way ANOVA. Statistical significance was set at p < 0.05. The numbers of independent replicates (n) are reported in the figure legends.
